ClinicalTrials.gg
RecruitingNCT06361485Updated Apr 11, 2024

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

A Phase 1 interventional study of Lumbar Injections with 10cc's of Wharton's Jelly Allograft in Low Back Pain, sponsored by R3 Stem Cell. Recruiting at 4 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by R3 Stem Cell · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Planned enrollment
263rd of 623
100 · median 79
Started
2024
with 31 others
Phase 1
25 of 712
5 open now
Primary completion
2027-03
later than 54 of 125 live
Registered
618th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 263rd largest by planned enrollment of the 623 interventional ones that give a count, is one of 32 that started in 2024, is one of 25 in phase 1, reaches primary completion later than 54 of the 125 other live ones, and was the 618th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

Read the detailed description

This is a prospective, open label, non-controlled Pilot study in which the safety and feasibility of umbilical cord Wharton's Jelly (WJ) allograft will be evaluated in participants suffering with lumbar pain. The participants will receive a series of lumbar injections described in the protocol.

As this is a Pilot study primarily designed to evaluate safety, no control will be used. The dosing will consist of 10cc WJ Allograft with 100 total participants. In addition to baseline outcome instruments along with imaging and laboratory studies, participants will be followed for one year for evaluation of safety, pain relief and functional improvements.

03

Conditions studied

  • Low Back Pain

Keywords

  • lumbago
  • low back pain
  • lumbar spondylosis
  • lumbar arthritis
  • facet syndrome
  • umbilical
  • umbilical cord allograft
  • stem cell
  • exosome
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must
  • Be over age 20.
  • Suffering from chronic lumbar pain
  • (BMI) \<50 Kilograms/m2.
  • Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS).
  • Female participants must be abstinent, surgically sterilized or .
  • Premenopausal females must be on measures and do not anticipate pregnancy during the duration of the study.
  • Be willing and capable of giving written to participate in English.
  • Be willing and capable of complying with study-related requirements, procedures and visits.

Exclusion criteria

Exclusion Criteria:

  • Patient must not
  • Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date.
  • Use anticoagulants have a substance abuse history, and fail to agree not to take any lumbar symptom modifying drugs during the course of the study without discussing and reporting the use to the site Clinical investigator and study team.
  • Known allergy to penicillin, sulfa or amphotericin medications.
  • Have had any lumbar injections (at all) of any drug in lumbar spine in the past 6 months.
  • Have had surgery on the lumbar spine within the past 6 months.
  • Had a traumatic injury to the lumbar spine with the past 3 months.
  • Planned elective surgery during the course of the study.
  • A history of organ or hematologic transplantation, rheumatoid arthritis, or other disorders.
  • Be on medications.
  • Have a diagnosis of carcinoma with the past 5 years.
  • Have a lumbar infection or have used antibiotics for lumbar infection within the past 3 months.
  • Have participated in any other clinical study or treatment (not just for the lumbar spine, but for any reason) with any product within the past 30 days prior to inclusion of study.
  • Female participants who are breast feeding or are pregnant or desire to become pregnant during the course of the study.
  • to radiographic or MRI imaging.
  • Serious neurological, psychological or psychiatric disorders.
  • Injury or disability claims under current litigation or pending or approved workers compensation claims.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Lumbar Injection Arm

    Lumbar Injections with 10cc's of Umbilical Cord Wharton's Jelly Allograft (BelloWJY)

    Biological: Lumbar Injections with 10cc's of Wharton's Jelly Allograft

Interventions

  • BiologicalLumbar Injections with 10cc's of Wharton's Jelly Allograft

    Low Back Injections with Minimal Manipulation Umbilical Cord Tissue

    Also known as: BelloWJY

06

What researchers measure

Primary outcomes

  1. C-reactive protein

    C-reactive protein (CRP) is a protein made by the liver. The level of CRP increases when there's inflammation in the body. A simple blood test can check your C-reactive protein level. C-reactive protein is measured in milligrams per liter (mg/L). Results equal to or greater than 8 mg/L or 10 mg/L are considered high. Range values vary depending on the lab doing the test. A high test result is a sign of inflammation. It may be due to serious infection, injury or chronic disease. Your health care provider may recommend other tests to determine the cause.

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  2. Erythrocyte sedimentation rate

    Sed rate, or erythrocyte sedimentation rate (ESR), is a blood test that can show inflammatory activity in the body. Because a sed rate test can't pinpoint the problem that's causing inflammation in your body, it's often accompanied by other blood tests, such as the C-reactive protein (CRP) test. ESR is measured in millimeters per hour (mm/hr). The normal values are: 0 to 15 mm/hr in men 0 to 20 mm/hr in women

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  3. Alanine transaminase (ALT)

    ALT is an enzyme that converts proteins into energy for the liver cells. Aspartate transaminase (AST). AST is an enzyme that helps the body break down amino acids. Alkaline phosphatase (ALP). ALP is an enzyme important for breaking down proteins. Albumin and total protein. Albumin is a protein made in the liver. Bilirubin. Bilirubin is a substance produced during the breakdown of red blood cells. Gamma-glutamyltransferase (GGT). Higher-than-usual may mean liver damage. L-lactate dehydrogenase (LD). LD is an enzyme found in the liver. Prothrombin time (PT). PT is the time it takes your blood to clot. Standard range: Alanine transaminase (ALT). ALT is an enzyme that converts proteins into energy for the liver cells. Standard range: ALT. 7 to 55 units per liter U/L.

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  4. Aspartate transaminase (AST)

    AST is an enzyme that helps the body break down amino acids. . Standard range: AST 8 to 48 units per liter

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  5. Alkaline phosphatase (ALP)

    ALP is an enzyme important for breaking down proteins. Standard range: 40 to 129 units per liter

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  6. Albumin

    Albumin is a protein made in the liver. Normal range is 34 to 54 grams/liter.

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  7. Creatinine

    Creatinine is a waste product that comes from the digestion of protein in your food and the normal breakdown of muscle tissue. It is removed from the blood through your kidneys. Everyone has some creatinine in their blood, but too much can be a sign of a possible kidney problem. Normal range is 0.6-1.3 milligrams/deciliter

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

  8. Blood Urea Nitrogen (BUN)

    blood urea nitrogen (BUN) test reveals important information about how well your kidneys are working. A BUN test measures the amount of urea nitrogen that's in your blood. Normal BUN is 6-20 milligrams/deciliter.

    Time frame: Baseline, 1 week after the procedure, 6 weeks, 3 months, 6 months and one year

Secondary outcomes

  1. 36-Item Short Form Survey (SF-36)

    The SF-36 is used as an assessment tool to measure a quality of life. The SF-36 is comprehensive health survey with a total of 36 questions divided into eight categories, including physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). The score averages for each category range from 0 to 100, with a higher score defining a more favorable outcome.

    Time frame: Baseline, 24 hours after intervention, 1 week, 6 weeks, 3 months, 6 months, 1 year

  2. Numerical Pain Rating Scale (NPRS)

    The Numerical Pain Rating Scale (NPRS) is a subjective measure in which individuals rate their pain on an eleven-point numerical scale. The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).

    Time frame: Baseline, 24 hours after intervention, 1 week, 6 weeks, 3 months, 6 months, 1 year

  3. Oswestry disability index (ODI)

    The Oswestry Disability Index (ODI) is a common questionnaire used to evaluate functional outcomes and physical functioning in patients with acute or chronic low back pain. This questionnaire yields a subjective percentage score that grades the level of physical function or disability. The cumulative score indicates the patient as functioning at a point on a range from minimal disability to bedbound. Each item consists of 6 statements (scores 0-5) and is scored by the patient in reference to his/her current functional status. A sum is formed from the points given, which is then divided by the maximum value (50 points). If only one question remains unanswered, the maximum value drops accordingly to 45 points and the score can be evaluated normally. The resulting score is then multiplied by 100 to provide a percentage which is referred to as the total score which ranges from 1 - 100%, with higher scores indicating a more severe disability.

    Time frame: Baseline, 1 week, 6 weeks, 3 months, 6 months, 1 year

  4. Roland Morris disability questionnaire (RMQ)

    The RMQ is a 24-item patient-reported outcome measure that inquires about pain-related disability resulting from low back pain. Items are scored 0 if left blank or 1 if endorsed, for a total RMQ score ranging from 0 to 24; higher scores represent higher levels of pain-related disability.

    Time frame: Baseline, 1 week, 6 weeks, 3 months, 6 months, 1 year

  5. The Patient-specific functional scale (PSFS)

    This is a patient-specific questionnaire that requires patients to identify up to five important activities that they are having difficulty with as a result of their condition. The patient rates difficulty on an 11-point numerical scale (0 = unable to perform the activity; 10 = able to perform activity at the same level as before the injury or problem). The average score for up to five activities is established as the PSFS score. This scale has been established as reliable, valid, and responsive in a number of patient populations, including patients with low back pain. Higher scores indicate better functioning.

    Time frame: Baseline, 1 week, 6 weeks, 3 months, 6 months, 1 year

07

Study locations

4 of 4 sites recruiting
08

References and documents

Publications

  • Godoy-Brewer GM, Owodunni OP, Parian AM, Duraes LC, Selaru FM, Gearhart SL. Initial Clinical Outcomes Using Umbilical Cord-Derived Tissue Grafts to Repair Anovaginal Fistula. Dis Colon Rectum. 2023 Feb 1;66(2):299-305. doi: 10.1097/DCR.0000000000002258. Epub 2022 Jan 4. PubMed 35001050 ↗
  • Gibson JN, Grant IC, Waddell G. The Cochrane review of surgery for lumbar disc prolapse and degenerative lumbar spondylosis. Spine (Phila Pa 1976). 1999 Sep 1;24(17):1820-32. doi: 10.1097/00007632-199909010-00012. PubMed 10488513 ↗
  • Gibson JN, Waddell G. Surgery for degenerative lumbar spondylosis: updated Cochrane Review. Spine (Phila Pa 1976). 2005 Oct 15;30(20):2312-20. doi: 10.1097/01.brs.0000182315.88558.9c. PubMed 16227895 ↗
  • Deyo RA, Weinstein JN. Low back pain. N Engl J Med. 2001 Feb 1;344(5):363-70. doi: 10.1056/NEJM200102013440508. No abstract available. PubMed 11172169 ↗
  • Magora A, Schwartz A (1976) Relation between the low back pain syndrome and x-ray findings. I. Degenerative osteoarthritis. Scand J Rehab Med 8:115 - 125
  • Schmorl G, Junghanns H (1968) Die gesunde und die kranke Wirbelsäule in Röntgenbild und Klinik. Thieme, Stuttgart
  • Hanley EN Jr, David SM. Lumbar arthrodesis for the treatment of back pain. J Bone Joint Surg Am. 1999 May;81(5):716-30. doi: 10.2106/00004623-199905000-00015. No abstract available. PubMed 10360702 ↗
  • Fritzell P, Hagg O, Nordwall A; Swedish Lumbar Spine Study Group. Complications in lumbar fusion surgery for chronic low back pain: comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group. Eur Spine J. 2003 Apr;12(2):178-89. doi: 10.1007/s00586-002-0493-8. Epub 2003 Feb 14. PubMed 12709856 ↗
  • Boswell MV, Colson JD, Sehgal N, Dunbar EE, Epter R. A systematic review of therapeutic facet joint interventions in chronic spinal pain. Pain Physician. 2007 Jan;10(1):229-53. PubMed 17256032 ↗
  • Gupta A, Maffulli N. Allogenic Umbilical Cord Tissue for Treatment of Knee Osteoarthritis. Sports Med Arthrosc Rev. 2022 Sep 1;30(3):162-165. doi: 10.1097/JSA.0000000000000350. Epub 2022 Aug 3. PubMed 35921598 ↗
  • Evaluation of the Efficacy of Cryopreserved Human Umbilical Cord Tissue Allografts to Augment Functional and Pain Outcome Measures in Patients with Knee Osteoarthritis: An Observational Data Collection Study, Davis et al, Physiologia 2022, 2(3), 109-120
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 11, 2024
StartActual
Mar 25, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Apr 1, 2028
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06361485
Lead sponsor
R3 Stem Cell
Collaborators
R3 Medical Research
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Mar 25, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Apr 11, 2024

Study contacts

David L Greene, MD, PhD, MBA
Contact
dgreene@r3medicalresearch.com
(602) 677-8981
Katherine Minter-Dykhouse, PhD
Contact
kmd@bello.bio
4803066256
James Faber, BA
study chair · Institute of Cellular and Regenerative Medicine IRB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion